InterCure Ltd. (INCR)
Market Cap | 120.31M |
Revenue (ttm) | 112.41M |
Net Income (ttm) | 4.39M |
Shares Out | 45.57M |
EPS (ttm) | 0.12 |
PE Ratio | 22.25 |
Forward PE | 6.94 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 12,372 |
Open | 2.560 |
Previous Close | 2.670 |
Day's Range | 2.630 - 2.690 |
52-Week Range | 0.990 - 2.920 |
Beta | 0.24 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 13, 2024 |
About INCR
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. [Read more]
Full Company ProfileFinancial Performance
In 2022, InterCure's revenue was 388.68 million, an increase of 76.93% compared to the previous year's 219.68 million. Earnings were 42.68 million, an increase of 810.00%.
Financial numbers in ILS Financial StatementsNews
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 202...
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside ...
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape
LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), her...
InterCure Provides an Update Regarding Nir Oz Facility
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Wins Cannolam Arbitration Proceeding
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Provides an Update Regarding the Security Situation in Israel
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), announced today that...
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), reports today that, ...
InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net curre...
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medica...
InterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In Israel
NEW YORK, TORONTO, and HERZLIYA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading cannabis ...
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson's premium cannabis brand Leadin...
InterCure Reschedules 2022 Full Year Results Conference Call
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that i...
InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
Record fiscal year 202 2 revenue of $ 150 million
InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK, TORONTO, and HERZLIYA, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) the biggest and most pro...
InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)
NEW YORK and TORONTO and HERZLIYA, Israel, Feb. 01, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") announces that, furth...
InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"
Leading Global Pharmaceutical Cannabis Company, InterCure, entered into an agreement with Praetorian Global, Inc. to license, manufacture and distribute the Florida-based cannabis brand ”Binske” Leadi...
InterCure to Participate in Cowen 5th Annual Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate
InterCure Announces the Withdrawal of a Class Action Lawsuit against it
NEW YORK and TORONTO and HERZLIYA, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announc...
Update regarding Better Transaction
NEW YORK and TORONTO and HERZLIYA, Israel, Nov. 23, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") is hereby providing an...
Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
Organigram to supply Israeli pharmaceutical grade cannabis leader InterCure with up to 20,000 kg of dried flower over multiple years Organigram to supply Israeli pharmaceutical grade cannabis leader I...
Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies
TORONTO & HERZILA, Israel--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), ( “Organigram”) a leading Canadian licensed producer of cannabis and Canndoc Ltd. (“Canndoc”), a subsid...